VIENNA, November 2021: Co-Founder Dr. Nikolaus Gasche has been recognised as one of the top 30 people under 30 from the 2021 edition of the Forbes DACH! (https://www.forbes.at/artikel/nikolaus-gasche.html)
Every year DACH Forbes 30 under 30 recognises the most successful entrepreneurs, founders, scientists, athletes and artists from Austria, Germany and Switzerland.
“It is an honour being on the Forbes 30 under 30 list and a great acknowledgement of the work of the whole team!” says Nikolaus Gasche.
Biome Diagnostics congratulates Nikolaus Gasche and is proud of this achievement!
About BiomeOne®
BiomeOne describes the current efforts of BiomeDx towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker that can be used for any tumor type. Read more on BiomeOne.
About BiomeDx®
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.